Prosecutors contend Martoma got nonpublic information from a physician about a clinical trial of an Alzheimer's drug, and then used that information to help CR Intrinsic Investors, an SAC division, avoid $276 million in losses through the sale of securities for Elan and Wyeth, now owned by Pfizer Inc. Martoma's case will go before a jury not long after the expected conclusion of a trial in New York of another SAC portfolio manager, Michael Steinberg. He is accused of trading in Dell Inc and Nvidia Corp, based on inside information. Once a $14 billion hedge fund, SAC Capital agreed last month to pay $1.2 billion and plead guilty to fraud charges as part of the insider trading probe. Cohen, who has not been criminally charged, faces an SEC administrative action accusing him of failing to supervise Martoma and Steinberg and prevent insider trading.